Healthcare shares split between trial progress and cash concerns

• Cynata rose 27.27% after announcing a fully underwritten A$913,000 entitlement offer.
• Vitasora gained 15.38% as estimated quarterly revenue rose 38%, despite a sharp fall after its market reopening.
• Neurizon climbed 15.00% after the FDA said one trial could potentially support approval of NUZ-001.
• Neurotech and Cynata still face warnings about their ability to keep operating without more money.